{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:23:48Z","timestamp":1794673428468,"version":"4.9.1"},"reference-count":147,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["01GM1908D"],"award-info":[{"award-number":["01GM1908D"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["504745852"],"award-info":[{"award-number":["504745852"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["KFO 5023"],"award-info":[{"award-number":["KFO 5023"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["FI 2309\/2-1"],"award-info":[{"award-number":["FI 2309\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neurol.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:38:05Z","timestamp":1727836685000},"page":"895-907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["MRI findings in autoimmune encephalitis"],"prefix":"10.1016","volume":"180","author":[{"given":"T.J.","family":"Hartung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kuchling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Leidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mantwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wurdack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yogeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.08.006_bib0740","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.08.006_bib0745","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ana.26241","article-title":"Long-term cognitive outcome in anti-N-methyl-D-aspartate receptor encephalitis","volume":"90","author":"Heine","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0750","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0755","doi-asserted-by":"crossref","first-page":"e200189","DOI":"10.1212\/NXI.0000000000200189","article-title":"The patient perspective in encephalitis research","volume":"11","author":"Finke","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0760","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0765","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0770","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S1474-4422(22)00299-X","article-title":"Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders","volume":"21","author":"Guasp","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0775","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/WNL.0000000000009987","article-title":"Sleep disorders in anti-NMDAR encephalitis","volume":"95","author":"Ari\u00f1o","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib0780","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuroscience.2015.05.037","article-title":"Imaging of autoimmune encephalitis\u00a0\u2013\u00a0Relevance for clinical practice and hippocampal function","volume":"309","author":"Heine","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurol.2024.08.006_bib0785","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0790","first-page":"716","article-title":"The challenge of integrating care in dual diagnosis; anti-NMDA-receptor encephalitis; presentation and outcome in 3 cases referred for complex specialist rehabilitation services","volume":"111","author":"Carroll","year":"2018","journal-title":"Irish Med J"},{"key":"10.1016\/j.neurol.2024.08.006_bib0795","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11606-011-1641-9","article-title":"Anti-NMDA-receptor encephalitis: case report and literature review of an under-recognized condition","volume":"26","author":"Day","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.neurol.2024.08.006_bib0800","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pediatrneurol.2014.01.012","article-title":"Pediatric anti-NMDA (N-methyl D-Aspartate) receptor encephalitis","volume":"50","author":"Salvucci","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0805","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10096-009-0799-0","article-title":"Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis","volume":"28","author":"Gable","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.neurol.2024.08.006_bib0810","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.neuropsych.17120343","article-title":"The psychiatric phenotype of anti-NMDA receptor encephalitis","volume":"31","author":"Gibson","year":"2019","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.neurol.2024.08.006_bib0815","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/NXI.0000000000000958","article-title":"Long-term functional outcomes and relapse of anti-NMDA receptor encephalitis: a cohort study in Western China","volume":"8","author":"Gong","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0820","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-020-00999-2","article-title":"Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients","volume":"8","author":"Jiang","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurol.2024.08.006_bib0825","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/acn3.467","article-title":"Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis","volume":"4","author":"Jun","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0830","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib0835","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1212\/WNL.0b013e3181fc2a06","article-title":"Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin","volume":"75","author":"Pr\u00fcss","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib0840","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejpn.2020.10.001","article-title":"Clinical outcomes of pediatric Anti-NMDA receptor encephalitis","volume":"29","author":"Shim","year":"2020","journal-title":"Eur J Paediatric Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0845","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/acn3.557","article-title":"Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis","volume":"5","author":"Shin","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0850","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3389\/fneur.2019.01330","article-title":"Psychiatric symptoms of patients with anti-NMDA receptor encephalitis","volume":"10","author":"Wang","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0855","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/0883073816643406","article-title":"Approach to the management of pediatric-onset anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis: a case series","volume":"31","author":"Brenton","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0860","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2015.02.010","article-title":"Focal seizures in children with anti-NMDA receptor antibody encephalitis","volume":"112","author":"Sands","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.08.006_bib0865","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamaneurol.2016.0232","article-title":"Association of progressive cerebellar atrophy with long-term outcome in patients with anti-N-Methyl-D-Aspartate receptor encephalitis","volume":"73","author":"Iizuka","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0870","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00415-010-5604-6","article-title":"Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study","volume":"257","author":"Iizuka","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0875","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/acn3.51604","article-title":"Disease progression and brain atrophy in NMDAR encephalitis: associated factor & clinical implication","volume":"9","author":"Lee","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0880","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1212\/WNL.0000000000006783","article-title":"A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis","volume":"92","author":"Balu","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib0885","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1212\/NXI.0000000000000860","article-title":"Validation of the NEOS score in Chinese patients with anti-NMDAR encephalitis","volume":"7","author":"Peng","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0890","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ana.25754","article-title":"Clinical and magnetic resonance imaging outcome predictors in pediatric anti-N-Methyl-D-Aspartate receptor encephalitis","volume":"88","author":"Bartels","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0895","doi-asserted-by":"crossref","first-page":"e958","DOI":"10.1212\/NXI.0000000000000958","article-title":"Long-term functional outcomes and relapse of anti-NMDA receptor encephalitis: a cohort study in Western China","volume":"8","author":"Gong","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0900","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ane.13160","article-title":"Long-term cognitive and neuropsychiatric outcomes in patients with anti-NMDAR encephalitis","volume":"140","author":"Liu","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2024.08.006_bib0905","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1212\/NXI.0000000000000633","article-title":"Anti-NMDAR encephalitis: a single-center, longitudinal study in China","volume":"7","author":"Xu","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0910","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0915","doi-asserted-by":"crossref","first-page":"e200130","DOI":"10.1212\/NXI.0000000000200130","article-title":"MRI features and their association with outcomes in children with anti-NMDA receptor encephalitis","volume":"10","author":"Gombolay","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0920","doi-asserted-by":"crossref","first-page":"105061","DOI":"10.1016\/j.msard.2023.105061","article-title":"Brain magnetic resonance imaging as predictors in pediatric anti-N-methyl-D-aspartate receptor encephalitis","volume":"82","author":"Hou","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2024.08.006_bib0925","doi-asserted-by":"crossref","first-page":"e200102","DOI":"10.1212\/NXI.0000000000200102","article-title":"Retrospective pediatric cohort study validates NEOS Score and demonstrates applicability in children with anti-NMDAR encephalitis","volume":"10","author":"Nikolaus","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0930","doi-asserted-by":"crossref","first-page":"e200235","DOI":"10.1212\/NXI.0000000000200235","article-title":"Very long-term functional outcomes and dependency in children with anti-NMDA receptor encephalitis","volume":"11","author":"Chen","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0935","doi-asserted-by":"crossref","first-page":"e1997","DOI":"10.1212\/WNL.0000000000005605","article-title":"Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis","volume":"90","author":"de Bruijn","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib0940","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaneurol.2014.1817","article-title":"Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis","volume":"72","author":"Fleischmann","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0945","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1212\/NXI.0000000000000141","article-title":"NMDA receptor antibodies: a rare association in inflammatory demyelinating diseases","volume":"2","author":"Ramberger","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0950","doi-asserted-by":"crossref","first-page":"1088801","DOI":"10.3389\/fimmu.2023.1088801","article-title":"Overlapping anti-NMDAR encephalitis and multiple sclerosis: a case report and literature review","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0955","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0960","doi-asserted-by":"crossref","first-page":"595417","DOI":"10.3389\/fimmu.2020.595417","article-title":"Case report: overlapping multiple sclerosis with anti-N-Methyl-D-Aspartate receptor encephalitis: a case report and review of literature","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0965","series-title":"ECTRIMS","article-title":"NMDA receptor encephalitis and multiple sclerosis overlap syndrome \u2013 Part I: clinical findings and MRI characteristics","author":"Kuchling","year":"2024"},{"key":"10.1016\/j.neurol.2024.08.006_bib0970","doi-asserted-by":"crossref","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE Registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib0975","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.08.006_bib0980","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458520951046","article-title":"MOG-IgG1 and co-existence of neuronal autoantibodies","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2024.08.006_bib0985","doi-asserted-by":"crossref","first-page":"e2302","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib0990","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib0995","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1212\/NXI.0000000000000002","article-title":"NMDA receptor antibodies associated with distinct white matter syndromes","volume":"1","author":"Hacohen","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1000","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.biopsych.2015.02.024","article-title":"Structural hippocampal damage following anti-N-Methyl-D-Aspartate receptor encephalitis","volume":"79","author":"Finke","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1005","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ana.23932","article-title":"Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis","volume":"74","author":"Finke","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1010","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S2215-0366(17)30330-9","article-title":"Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study","volume":"4","author":"Peer","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/jnnp-2017-316822","article-title":"Superficial white matter damage in anti-NMDA receptor encephalitis","volume":"89","author":"Phillips","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1020","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/ejn.15901","article-title":"Reduced resilience of brain state transitions in anti-N-methyl-D-aspartate receptor encephalitis","volume":"57","author":"Von Schwanenflug","year":"2023","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurol.2024.08.006_bib1025","doi-asserted-by":"crossref","first-page":"fcab298","DOI":"10.1093\/braincomms\/fcab298","article-title":"State-dependent signatures of anti-N-methyl-D-aspartate receptor encephalitis","volume":"4","author":"von Schwanenflug","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2024.08.006_bib1030","first-page":"366","article-title":"The T1-weighted\/T2-weighted ratio as a biomarker of anti-NMDA receptor encephalitis","volume":"95","author":"Hartung","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1035","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1040","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1050","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1474-4422(23)00463-5","article-title":"Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study","volume":"23","author":"Mu\u00f1oz-Lopetegi","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","article-title":"Evaluation of Cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies","volume":"74","author":"Finke","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1060","doi-asserted-by":"crossref","first-page":"e200179","DOI":"10.1212\/NXI.0000000000200179","article-title":"Neuropsychological testing in autoimmune encephalitis: a scoping review","volume":"11","author":"Galioto","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1355617722000509","article-title":"Cognitive outcomes in anti-LGI-1 encephalitis","volume":"29","author":"Galioto","year":"2023","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.neurol.2024.08.006_bib1075","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz-Lopetegi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1080","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/acn3.52006","article-title":"Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis","volume":"11","author":"Binks","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jamaneurol.2021.0477","article-title":"Residual fatigue and cognitive deficits in patients after leucine-rich glioma-inactivated 1 antibody encephalitis","volume":"78","author":"Binks","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1090","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1095","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1212\/NXI.0000000000000161","article-title":"Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures","volume":"2","author":"Flanagan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1100","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1212\/NXI.0000000000000336","article-title":"Striking basal ganglia imaging abnormalities in LGI1 ab faciobrachial dystonic seizures","volume":"4","author":"L\u00f3pez Chiriboga","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1105","doi-asserted-by":"crossref","first-page":"618109","DOI":"10.3389\/fneur.2020.618109","article-title":"Brain magnetic resonance imaging characteristics of anti-leucine-rich glioma-inactivated 1 encephalitis and their clinical relevance: a single-center study in China","volume":"11","author":"Shao","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1110","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1115","doi-asserted-by":"crossref","first-page":"e200228","DOI":"10.1212\/NXI.0000000000200228","article-title":"Predictors and clinical characteristics of relapses in LGI1-antibody encephalitis","volume":"11","author":"Campetella","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1120","first-page":"1053","article-title":"Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis","volume":"11","author":"Kelly","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1125","doi-asserted-by":"crossref","first-page":"578346","DOI":"10.1016\/j.jneuroim.2024.578346","article-title":"Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies","volume":"390","author":"Campetella","year":"2024","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1130","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/brain\/awx070","article-title":"Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis","volume":"140","author":"Miller","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1135","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis","volume":"87","author":"Van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1140","doi-asserted-by":"crossref","first-page":"e200178","DOI":"10.1212\/NXI.0000000000200178","article-title":"Clinical determinants of longitudinal disability in LGI-1-IgG autoimmune encephalitis","volume":"11","author":"Aboseif","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1145","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/jnnp-2017-317780","article-title":"Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis","volume":"89","author":"Heine","year":"2018","journal-title":"J NeurolJ Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1150","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/jnnp-2017-317780","article-title":"Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis","volume":"89","author":"Heine","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1490","article-title":"Persistent cognitive deficits in anti-LGI1 encephalitis are linked to a reorganization of structural brain networks. Study on cognitive deficits in LGI1 encephalitis and white matter networks","author":"Krohn","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.neurol.2024.08.006_bib1155","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/jnnp-2020-323226","article-title":"Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features","volume":"91","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.22297","article-title":"Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia","volume":"69","author":"Lancaster","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1165","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","article-title":"Characterization of a subtype of autoimmune encephalitis with anti-Contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures","volume":"73","author":"Joubert","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13180","article-title":"Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome","volume":"24","author":"Bien","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG\u2013positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1180","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1212\/NXI.0000000000000075","article-title":"Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis","volume":"2","author":"K\u00f6rtvelyessy","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1185","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/jnnp-2011-301506","article-title":"Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia","volume":"83","author":"Becker","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1195","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/brain\/awac119","article-title":"A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies","volume":"146","author":"Strippel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1200","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211003486","article-title":"GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions","volume":"14","author":"Tsiortou","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2024.08.006_bib1205","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/ene.12186","article-title":"Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis","volume":"20","author":"Frisch","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yebeh.2016.10.016","article-title":"Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis","volume":"65","author":"Hansen","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.08.006_bib1215","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jnnp-2014-307875","article-title":"Automated volumetry of the mesiotemporal structures in antibody-associated limbic encephalitis","volume":"86","author":"Wagner","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1220","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fneur.2015.00130","article-title":"Loss of autonoetic consciousness of recent autobiographical episodes and accelerated long-term forgetting in a patient with previously unrecognized glutamic acid decarboxylase antibody related limbic encephalitis","volume":"6","author":"Witt","year":"2015","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1225","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1469-8749.2008.03217.x","article-title":"Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency","volume":"51","author":"Akman","year":"2009","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1230","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1684\/epd.2018.0993","article-title":"Refractory epilepsy secondary to anti-GAD encephalitis treated with DBS post SEEG evaluation: a novel case report based on stimulation findings","volume":"20","author":"Gillinder","year":"2018","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2024.08.006_bib1235","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2014.05.032","article-title":"Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase","volume":"343","author":"Markakis","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2024.08.006_bib1240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13760-014-0332-9","article-title":"Idiopathic limbic encephalitis associated with antibodies to glutamic acid decarboxylase","volume":"115","author":"Millet","year":"2015","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.neurol.2024.08.006_bib1245","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/archneur.58.2.225","article-title":"Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients","volume":"58","author":"Honnorat","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1260","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1212\/NXI.0000000000000232","article-title":"Evidence of a pathogenic role for CD8+ T cells in anti-GABAB receptor limbic encephalitis","volume":"3","author":"Golombeck","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1265","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.4103\/0366-6999.168989","article-title":"Limbic encephalitis associated with anti-\u03b3-aminobutyric acid b receptor antibodies: a case series from China","volume":"128","author":"Guan","year":"2015","journal-title":"Chin Med J"},{"key":"10.1016\/j.neurol.2024.08.006_bib1270","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/jnnp-2014-308814","article-title":"Limbic encephalitis due to GABABand AMPA receptor antibodies: a case series","volume":"86","author":"Dogan Onugoren","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.006_bib1275","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/01616412.2017.1351062","article-title":"Encephalitis with antibodies against the GABAB receptor: seizures as the most common presentation at admission","volume":"39","author":"Chen","year":"2017","journal-title":"Neurol Res"},{"key":"10.1016\/j.neurol.2024.08.006_bib1280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-019-1585-y","article-title":"Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1285","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fneur.2020.00403","article-title":"Clinical characteristics of anti-GABA-B receptor encephalitis","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1290","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2012.12.006","article-title":"GABAB receptor antibodies in paraneoplastic cerebellar ataxia","volume":"256","author":"Jarius","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1295","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamaneurol.2013.4786","article-title":"Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures the first pediatric case of y-aminobutyric acid type B receptor autoimmunity","volume":"71","author":"Kruer","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1300","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jneuroim.2013.04.004","article-title":"GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis","volume":"259","author":"Mundiyanapurath","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1305","doi-asserted-by":"crossref","first-page":"509","DOI":"10.12809\/hkmj154604","article-title":"A case of refractory seizure with cognitive impairment due to anti-GABA encephalitis case report","volume":"22","author":"Hui","year":"2016","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.neurol.2024.08.006_bib1310","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/NRL.0000000000000283","article-title":"GABA-B receptor encephalitis triggered by enterovirus encephalitis in a patient with small cell lung cancer: a case report","volume":"25","author":"Kim","year":"2020","journal-title":"Neurologist"},{"key":"10.1016\/j.neurol.2024.08.006_bib1315","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2014.04.009","article-title":"Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF","volume":"272","author":"DeFelipe-Mimbrera","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1320","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3892\/etm.2020.8684","article-title":"Clinical features and outcomes of Chinese patients with anti-\u03b3-aminobutyric acid B receptor encephalitis","volume":"20","author":"Zhao","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.neurol.2024.08.006_bib1325","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1330","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1335","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.0000000000001326","article-title":"Antibodies to GABAA receptor 1 and 2 subunits: clinical and serologic characterization","volume":"84","author":"Pettingill","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1340","doi-asserted-by":"crossref","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and characterization of movement disorders in anti-IgLON5 disease","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1345","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1350","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/WCO.0000000000001271","article-title":"New knowledge on anti-IgLON5 disease","volume":"37","author":"Gaig","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1355","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gr\u00fcter","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1360","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1365","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2024.08.006_bib1370","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1375","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/brain\/awae048","article-title":"HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease","volume":"147","author":"Yogeshwar","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.08.006_bib1380","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1385","first-page":"e13386","article-title":"IgLON 5 antibody syndrome: isolated case of a patient with indolent disease progression and unusual MRI findings","volume":"13","author":"Park","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.neurol.2024.08.006_bib1390","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000005859","article-title":"IgLON5: a case with predominant cerebellar tau deposits and leptomeningeal inflammation","volume":"91","author":"Sch\u00f6berl","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1395","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fneur.2018.00329","article-title":"IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes","volume":"9","author":"Montagna","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1400","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1212\/NXI.0000000000000485","article-title":"Subacute encephalitis with recovery in IgLON5 autoimmunity","volume":"5","author":"Ramanan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1405","doi-asserted-by":"crossref","first-page":"800298","DOI":"10.3389\/fneur.2022.800298","article-title":"Epileptic seizures and right-sided hippocampal swelling as presenting symptoms of anti-IgLON5 disease: a case report and systematic review of the literature","volume":"13","author":"Fu","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1410","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.radcr.2024.03.041","article-title":"Atypical brain MRI findings in a patient with treatment responsive anti-IgLON5 disease","volume":"19","author":"Zandiehvakili","year":"2024","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.neurol.2024.08.006_bib1415","doi-asserted-by":"crossref","first-page":"e200153","DOI":"10.1212\/NXI.0000000000200153","article-title":"Trigeminal nerve involvement in bulbar-onset anti-IgLON5 disease","volume":"10","author":"Cluse","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.006_bib1420","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaneurol.2019.3638","article-title":"Distinctive magnetic resonance imaging findings in IgLON5 antibody disease","volume":"77","author":"Chen","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1425","doi-asserted-by":"crossref","first-page":"e2325","DOI":"10.1212\/WNL.0000000000207870","article-title":"In vivo measurement of tau depositions in anti-IgLON5 disease using [18F]PI-2620 PET","volume":"101","author":"Theis","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.006_bib1430","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00401-023-02625-6","article-title":"Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease","volume":"146","author":"Berger-Sieczkowski","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1435","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1440","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/diagnostics12040849","article-title":"Neuroimaging findings in a patient with anti-IgLON5 disease: cerebrospinal fluid dynamics abnormalities","volume":"12","author":"Urso","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.neurol.2024.08.006_bib1445","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1450","doi-asserted-by":"crossref","first-page":"e16284","DOI":"10.1111\/ene.16284","article-title":"Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: a systematic review and meta-analysis","volume":"31","author":"Hagbohm","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1455","doi-asserted-by":"crossref","first-page":"1375971","DOI":"10.3389\/fneur.2024.1375971","article-title":"Clinical characteristics and MRI features of autoimmune glial fibrillary acidic protein astrocytopathy: a case series of 34 patients","volume":"15","author":"Ke","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1460","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2023.0606","article-title":"Severe hippocampal atrophy in a patient with autoimmune glial fibrillary acidic protein astrocytopathy","volume":"80","author":"Bartels","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.006_bib1465","doi-asserted-by":"crossref","first-page":"611194","DOI":"10.3389\/fnins.2020.611194","article-title":"Quantitative multi-parameter mapping optimized for the clinical routine","volume":"14","author":"Cooper","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurol.2024.08.006_bib1470","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/jnnp-2017-316822","article-title":"Superficial white matter damage in anti-NMDA receptor encephalitis","volume":"89","author":"Phillips","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:36:15Z","timestamp":1730396175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724005903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":147,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0035378724005903"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.08.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRI findings in autoimmune encephalitis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}